Primary |
Drug Use For Unknown Indication |
14.7% |
Sepsis |
12.7% |
Pneumonia |
9.1% |
Infection |
8.1% |
Hypertension |
6.2% |
Pain |
4.9% |
Fluid Replacement |
4.6% |
Neutropenic Sepsis |
4.6% |
Urinary Tract Infection |
4.6% |
Prophylaxis |
4.2% |
Bronchiectasis |
3.6% |
Cholecystitis |
3.6% |
Metastatic Gastric Cancer |
2.9% |
Pyrexia |
2.9% |
Anti-infective Therapy |
2.3% |
Epilepsy |
2.3% |
Lower Respiratory Tract Infection |
2.3% |
Pneumonia Aspiration |
2.3% |
Pneumonitis |
2.3% |
Acute Myeloid Leukaemia |
2.0% |
|
Rash |
8.6% |
Interstitial Lung Disease |
6.9% |
Septic Shock |
6.9% |
Toxic Skin Eruption |
6.9% |
White Blood Cell Count Decreased |
6.9% |
Death |
6.0% |
Pyrexia |
6.0% |
Vomiting |
6.0% |
Dermatitis Exfoliative |
5.2% |
Thrombocytopenia |
5.2% |
Megacolon |
4.3% |
Cardio-respiratory Arrest |
3.4% |
Jaundice |
3.4% |
Laryngeal Oedema |
3.4% |
Liver Disorder |
3.4% |
Pneumonia Klebsiella |
3.4% |
Renal Failure Acute |
3.4% |
Sepsis |
3.4% |
Shock |
3.4% |
Skin Haemorrhage |
3.4% |
|
Secondary |
Product Used For Unknown Indication |
33.1% |
Drug Use For Unknown Indication |
16.2% |
Pneumonia Aspiration |
7.9% |
Pneumonia |
4.6% |
Lower Respiratory Tract Infection |
4.1% |
Pseudomonas Infection |
4.1% |
Pain |
3.6% |
Sepsis |
3.3% |
Cholecystitis |
3.0% |
Acute Myeloid Leukaemia |
3.0% |
Respiratory Failure |
2.9% |
Infection |
2.4% |
Myelodysplastic Syndrome |
2.1% |
Pyrexia |
2.1% |
Staphylococcal Infection |
1.4% |
Urinary Tract Infection |
1.3% |
Bacteraemia |
1.2% |
Epilepsy |
1.2% |
Peritonitis Bacterial |
1.2% |
Prophylaxis |
1.2% |
|
Venoocclusive Liver Disease |
19.8% |
White Blood Cell Count Increased |
8.8% |
Toxic Epidermal Necrolysis |
6.0% |
Intestinal Dilatation |
5.5% |
Liver Function Test Abnormal |
5.5% |
Platelet Count Increased |
5.5% |
Venoocclusive Disease |
5.5% |
Megacolon |
4.9% |
Vomiting |
4.4% |
Dermatitis Exfoliative |
3.3% |
Interstitial Lung Disease |
3.3% |
Renal Failure |
3.3% |
Renal Failure Acute |
3.3% |
Stevens-johnson Syndrome |
3.3% |
Toxic Encephalopathy |
3.3% |
Weight Decreased |
3.3% |
Clostridium Difficile Infection |
2.7% |
Nausea |
2.7% |
Thrombocytopenia |
2.7% |
Urticaria |
2.7% |
|
Concomitant |
Product Used For Unknown Indication |
30.9% |
Drug Use For Unknown Indication |
14.4% |
Prophylaxis |
12.2% |
Acute Myeloid Leukaemia |
4.9% |
Hypertension |
4.7% |
Pneumonia |
4.5% |
Pain |
3.2% |
Infection |
2.8% |
Nausea |
2.8% |
Antibiotic Therapy |
2.7% |
Sepsis |
2.3% |
Diffuse Large B-cell Lymphoma |
2.1% |
Infection Prophylaxis |
1.8% |
Pyrexia |
1.8% |
Ascites |
1.6% |
Antifungal Prophylaxis |
1.5% |
Constipation |
1.5% |
Neoplasm Malignant |
1.4% |
Prophylaxis Of Nausea And Vomiting |
1.4% |
Sedation |
1.4% |
|
Thrombocytopenia |
13.3% |
Sepsis |
10.3% |
Pyrexia |
7.0% |
Septic Shock |
6.6% |
Renal Failure Acute |
6.3% |
Pneumonia |
5.0% |
Tachycardia |
5.0% |
Toxic Epidermal Necrolysis |
4.7% |
White Blood Cell Count Decreased |
4.7% |
White Blood Cell Count Increased |
4.3% |
Tumour Lysis Syndrome |
4.0% |
Death |
3.7% |
Febrile Neutropenia |
3.7% |
Neutropenia |
3.3% |
Renal Failure |
3.3% |
Respiratory Failure |
3.3% |
Neutropenic Sepsis |
3.0% |
Urinary Tract Infection |
3.0% |
Weight Decreased |
3.0% |
Rash |
2.7% |
|
Interacting |
Pleural Effusion |
20.0% |
Renal Transplant |
20.0% |
Atrial Fibrillation |
10.0% |
Deep Vein Thrombosis |
10.0% |
Interstitial Lung Disease |
10.0% |
Pneumocystis Jiroveci Pneumonia |
10.0% |
Pneumonia |
10.0% |
Urinary Tract Infection Fungal |
10.0% |
|
Pneumonia |
33.3% |
Rash |
33.3% |
Ulcer |
33.3% |
|